Limits...
Meta-analysis of Selective Serotonin Reuptake Inhibitors (SSRIs) Compared to Tricyclic Antidepressants (TCAs) in the Efficacy and Safety of Anti-depression Therapy in Parkinson's Disease(PD) Patients.

Qiu BY, Qiao JX, Yong J - Iran J Pharm Res (2014)

Bottom Line: A computer-based search was conducted in the databases of PUBMED, MEDLINE, EMBASE and CochraneControlled Trails Register up to December 2011.Moreover, the incidence rate of xerostomia [RR 0.21, 95%CI (0.07, 0.65)] and constipation [RR 0.12, 95%CI(0.02, 0.63)] was lower in SSRIs group rather than those in TCAs group.However, SSRIs are superior to TCAs in the terms of xerostomia and constipation.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Engineering, General Hospital of the Second Artillery, Beijing 100088, China.

ABSTRACT
To assess the efficacy and safety of selective serotonin reuptake inhibitors(SSRIs) and tricyclic antidepressants(TCAs) in treatment of Parkinsonian depression. A computer-based search was conducted in the databases of PUBMED, MEDLINE, EMBASE and CochraneControlled Trails Register up to December 2011. The random controlled clinic trials about SSRIs and TCAs in treatment of Parkinsonian depression were collected. Statistical analysis was completed using Review Manager, version 5.0. Five clinic controlled trials were identified for this meta-analysis. There was no significant statistical difference in the response rate of treatment [RR 0.95, 95%CI (0.78, 1.16)] and Hamilton depression score [RR -2.54, 95%CI (-5.35, 0.26)] between two groups. In term of complications, no statistical difference was observed in the insomnia rate between two groups [RR 0.82, 95%CI (0.24, 2.84)]. Moreover, the incidence rate of xerostomia [RR 0.21, 95%CI (0.07, 0.65)] and constipation [RR 0.12, 95%CI(0.02, 0.63)] was lower in SSRIs group rather than those in TCAs group. In general, SSRIs and TCAs have comparable efficacy and equal acceptability in treatment of Parkinson's disease-induced depression. However, SSRIs are superior to TCAs in the terms of xerostomia and constipation.

No MeSH data available.


Related in: MedlinePlus

Meta-analysis of xerostomia rate between SSRIs group and TCAs group
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4232786&req=5

Figure 4: Meta-analysis of xerostomia rate between SSRIs group and TCAs group

Mentions: Two studies(10, 11)showed the xerostomia rate between SSRIs group and TCAs group in PD treatment. The incidence of xerostomia was significantly different between SSRIs and TCAs[RR 0.21, 95%CI (0.07, 0.65), P=0.007], using a fixed effects model due to the lack of significant heterogeneity in the data collected (P=0.54,I2=0%). This indicates that the occurrence of xerostomia favors SSRIs group rather than TCAs group (Figure 4).


Meta-analysis of Selective Serotonin Reuptake Inhibitors (SSRIs) Compared to Tricyclic Antidepressants (TCAs) in the Efficacy and Safety of Anti-depression Therapy in Parkinson's Disease(PD) Patients.

Qiu BY, Qiao JX, Yong J - Iran J Pharm Res (2014)

Meta-analysis of xerostomia rate between SSRIs group and TCAs group
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4232786&req=5

Figure 4: Meta-analysis of xerostomia rate between SSRIs group and TCAs group
Mentions: Two studies(10, 11)showed the xerostomia rate between SSRIs group and TCAs group in PD treatment. The incidence of xerostomia was significantly different between SSRIs and TCAs[RR 0.21, 95%CI (0.07, 0.65), P=0.007], using a fixed effects model due to the lack of significant heterogeneity in the data collected (P=0.54,I2=0%). This indicates that the occurrence of xerostomia favors SSRIs group rather than TCAs group (Figure 4).

Bottom Line: A computer-based search was conducted in the databases of PUBMED, MEDLINE, EMBASE and CochraneControlled Trails Register up to December 2011.Moreover, the incidence rate of xerostomia [RR 0.21, 95%CI (0.07, 0.65)] and constipation [RR 0.12, 95%CI(0.02, 0.63)] was lower in SSRIs group rather than those in TCAs group.However, SSRIs are superior to TCAs in the terms of xerostomia and constipation.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Engineering, General Hospital of the Second Artillery, Beijing 100088, China.

ABSTRACT
To assess the efficacy and safety of selective serotonin reuptake inhibitors(SSRIs) and tricyclic antidepressants(TCAs) in treatment of Parkinsonian depression. A computer-based search was conducted in the databases of PUBMED, MEDLINE, EMBASE and CochraneControlled Trails Register up to December 2011. The random controlled clinic trials about SSRIs and TCAs in treatment of Parkinsonian depression were collected. Statistical analysis was completed using Review Manager, version 5.0. Five clinic controlled trials were identified for this meta-analysis. There was no significant statistical difference in the response rate of treatment [RR 0.95, 95%CI (0.78, 1.16)] and Hamilton depression score [RR -2.54, 95%CI (-5.35, 0.26)] between two groups. In term of complications, no statistical difference was observed in the insomnia rate between two groups [RR 0.82, 95%CI (0.24, 2.84)]. Moreover, the incidence rate of xerostomia [RR 0.21, 95%CI (0.07, 0.65)] and constipation [RR 0.12, 95%CI(0.02, 0.63)] was lower in SSRIs group rather than those in TCAs group. In general, SSRIs and TCAs have comparable efficacy and equal acceptability in treatment of Parkinson's disease-induced depression. However, SSRIs are superior to TCAs in the terms of xerostomia and constipation.

No MeSH data available.


Related in: MedlinePlus